Skip to main content
Skip to footer site map
Ohio Attorney General Mike DeWine
Online Public Inspection File
Back to Search Results
Defendant agrees not to promote its antipsychotic, Seroquel, for off-label use. Prohibited actions include: 1) presenting patient profiles/types based on selected symptoms unless the drug's FDA-approved indications are stated clearly and conspicuously in the same spread, 2) financial incentives for marketing and/or sales personnel that encourage the improper promotion, sales, and marketing of Seroquel, 3) detailing Seroquel to providers who are unlikely to prescribe Seroquel for a use consistent with its FDA-approved indications, 4) distributing any medical articles, study results, reports, etc. that describe the off-label use of Seroquel that make any false, misleading, or deceptive representation about Seroquel or any competing product, 4) responding to requests from providers for medical articles, study results, or reports by sales or marketing personnel. Defendant is required to disclose information about medical education grants regarding Seroquel, including CME grants, and shall not use any type of grant to promote Seroquel, and to disclose information about payments made to U.S.-based physicians who served as a promotional speaker in the United States. Defendant to pay $68.5 million to the participating states.
Privacy and Disclaimers
| © 2009 Ohio Attorney General Richard Cordray